Sonnet biotherapeutics presents compilation of data highlighting the potential of son-1010 as a monotherapy or a combination therapy to improve the treatment of solid tumors

Poster presented at the 2025 aacr:io conference company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a fully-human, albumin binding scfv domain (f h ab ® )  provides enhanced targeting to the tumor microenvironment (tme) and prolonged retention in the tumor princeton, n.j., feb. 26, 2025 (globe newswire) -- sonnet biotherapeutics holdings, inc. (the “company” or “sonnet”) (nasdaq: sonn), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 american association for cancer research (aacr) io conference.
SONN Ratings Summary
SONN Quant Ranking